am Altman, the OpenAI CEO plans to further support the San Franciso startup Retro Biosciences, which focuses its operations on extending the human lifespan
by 10 years.
The OpenAI CEO has previously supported the Retro Biosciences seed round with about $180 million. To maintain the progress in this ambitious goal, the San Francisco startup is raising $1 billion in a Series A funding round which Sam Altman is expected to join, as the Financial Times stated.
Not long ago, Retro Biosciences, stated that they were planning to launch a trial for a certain medication that targets various diseases including Alzheimer's. Also, the company has successfully trained an artificial intelligence-powered model that is supposed to transform regular cells into stem cells.
However, the next funding found will be led by Sandro Salsano, an Italian financier who has recently joined the board.
“Right now if someone gets Alzheimer’s, it doesn’t matter what your resources are. You know, if you’re like Joe Biden, or Elon [Musk], or whoever, you can write as big a check as you want to anybody, and nobody knows how to cure it.”, Joe Betts-LaCroix, the Retro Biosciences CEO stated.
Subscribe to our newsletter
However, it seems that besides Sam Altman, other tech billionaires have been interested in increasing the human lifespan as well as the health span. To support this initiative, Jeff Bezos has supplied Alto Labs, the anti-aging startup, and also Peter Thiel has supported the Methuselah Foundation, an establishment that focuses on making “90 the new 50 by 2030.
So, in partnership with the OpenAI CEO, the San Francisco startup uses artificial intelligence technology in order to create certain proteins that can temporarily transform stem cells from regular cells, which are considered to reverse the process of aging.
It should be mentioned that Retro Biosciences, besides the early-stage study that targets various diseases including Alzheimer's, the company plans to use artificial intelligence to create cell therapies that will rejuvenate blood and brain cells.
“If you’re 85 years old and you undergo this therapy, you can replace your blood stem cells with ones that are zero age, and then those ripple out and produce all your blood,”, the Retro Biosciences CEO stated for the Financial Times.
San Franciso is determined to achieve these ambitious goals soon since they are planning to release the first medicine in the 2020s, so more specifically in the next 5 years.
By
Alice Brasoveanu
•
January 27, 2025 10:10 AM
